Safety Profile
Information not yet available for this ingredient profile.
Interactions
Information not yet available for this ingredient profile.
Evidence and Scientific Findings
Ingredient Overview
Xylanase is a carbohydrate-digesting enzyme that breaks down xylans (plant cell wall polysaccharides). Used in digestive enzyme blends to support digestion of high-fiber foods. Very safe at standard supplemental doses. No clinically significant adverse effects or drug interactions documented.
Biological and Chemical Classification
Information not yet available for this ingredient profile.
Mechanism of Action
Information not yet available for this ingredient profile.
Clinical Evidence of Effectiveness
Information not yet available for this ingredient profile.
Pharmacokinetics
Information not yet available for this ingredient profile.
Recommended Dosage
Information not yet available for this ingredient profile.
SETI — Scientific Evidence Transparency Index
Executive Summary — Ingredient Assessment
- 10 studies reviewed
- 0 high-quality studies (meta-analysis or RCT)
- Main clinical benefit observed: Enzymes
- Evidence consistency: High consistency across studies (100%)
- No significant safety signals identified in the reviewed literature.
The available scientific evidence for Xylanase indicates notable safety signals that warrant caution. Use should be considered carefully and monitored, particularly in sensitive populations or alongside other medications.
Total SETI Score
High risk| Evidence quality | 10/40 |
| Evidence consistency | 20/20 |
| Safety signals | 0/20 |
| Study recency | 10/10 |
| Evidence transparency | 10/10 |
Evidence Summary
- 10 studies reviewed
- 0 high-quality studies (meta-analysis or systematic review)
- 0 studies identified benefits or no safety concern (GREEN)
- 10 studies reported limited or advisory safety evidence (YELLOW)
Evidence Policy
Only peer-reviewed scientific literature indexed in PubMed or comparable databases is included in this evaluation. Commercial websites, blogs, and marketing materials are excluded. All references include direct traceable links to source documents.
Last updated: 06 აპრ 2026, 12:11
Evidence Distribution
-
Observational / other LOW evidence YELLOWCharacterization of a GH11 Xylanase from Endophytic Chaetomium globosum DX-THS3 with Excellent pH Stability and its Role in Enhancing Lignocellulose Degradation. ↗Ji R et al.. Characterization of a GH11 Xylanase from Endophytic Chaetomium globosum DX-THS3 with Excellent pH Stability and its Role in Enhancing Lignocellulose Degradation.. Appl Biochem Biotechnol. 2026. PMID:41915356.PMID 41915356 ↗Journal Appl Biochem BiotechnolYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41915356/
-
Observational / other LOW evidence YELLOWComparative Enzymology and Biomass Hydrolysis Reveal Industrial Biorefining Potential of Aspergillus fumigatus Strain VP2T. ↗Pal V et al.. Comparative Enzymology and Biomass Hydrolysis Reveal Industrial Biorefining Potential of Aspergillus fumigatus Strain VP2T.. Microorganisms. 2026. PMID:41900482.PMID 41900482 ↗Journal MicroorganismsYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41900482/
-
Observational / other LOW evidence YELLOWTemporal Variation in Mechanical and Chemical Properties of Bamboo Decayed by Schizophyllum commune QP33. ↗Guo X et al.. Temporal Variation in Mechanical and Chemical Properties of Bamboo Decayed by Schizophyllum commune QP33.. J Fungi (Basel). 2026. PMID:41893107.PMID 41893107 ↗Journal J Fungi (Basel)Year 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41893107/
-
Observational / other LOW evidence YELLOWOptimization of fermentation conditions for cellulase/xylanase production and hydrolysis conditions for efficient conversion of agricultural residues using Penicillium oxalicum UNN1. ↗Zhong L et al.. Optimization of fermentation conditions for cellulase/xylanase production and hydrolysis conditions for efficient conversion of agricultural residues using Penicillium oxalicum UNN1.. Bioresour Bioprocess. 2026. PMID:41886215.PMID 41886215 ↗Journal Bioresour BioprocessYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41886215/
-
Observational / other LOW evidence YELLOWProtein structure of a glycoside hydrolase family 30, subfamily 12 endo-1,4-u03b2-xylanase. ↗St John FJ et al.. Protein structure of a glycoside hydrolase family 30, subfamily 12 endo-1,4-u03b2-xylanase.. Acta Crystallogr D Struct Biol. 2026. PMID:41870978.PMID 41870978 ↗Journal Acta Crystallogr D Struct BiolYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41870978/
-
Observational / other LOW evidence YELLOWRSM-GA-BP optimization of Ultrasound-Enzyme-Assisted deep eutectic solvent extraction (UEADESE) for flavonoids from Abelmoschus manihot (L.) leaves and mechanistic insights. ↗Yang S et al.. RSM-GA-BP optimization of Ultrasound-Enzyme-Assisted deep eutectic solvent extraction (UEADESE) for flavonoids from Abelmoschus manihot (L.) leaves and mechanistic insights.. Ultrason Sonochem. 2026. PMID:41865723.PMID 41865723 ↗Journal Ultrason SonochemYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41865723/
-
Observational / other LOW evidence YELLOWGenomic and transcriptomic insights into Trichomonascus vanleenenianus, a xylan-degrading yeast isolated from saproxylic insect larvae. ↗Boisramu00e9 A et al.. Genomic and transcriptomic insights into Trichomonascus vanleenenianus, a xylan-degrading yeast isolated from saproxylic insect larvae.. BMC Genomics. 2026. PMID:41864865.PMID 41864865 ↗Journal BMC GenomicsYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41864865/
-
Observational / other LOW evidence YELLOWRational Design of Flexible Regions in a GH10 Xylanase from Paecilomyces aerugineus to Improve Its Thermostability, Catalytic Efficiency, and XOS Production from… ↗Yang H et al.. Rational Design of Flexible Regions in a GH10 Xylanase from Paecilomyces aerugineus to Improve Its Thermostability, Catalytic Efficiency, and XOS Production from Corn Stover.. J Agric Food Chem. 2026. PMID:41852143.PMID 41852143 ↗Journal J Agric Food ChemYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41852143/
-
Observational / other LOW evidence YELLOWN-acetylated chito-oligosaccharides and xylanase improve intestinal health and production performance in laying hens. ↗Van Hoeck V et al.. N-acetylated chito-oligosaccharides and xylanase improve intestinal health and production performance in laying hens.. Poult Sci. 2026. PMID:41850056.PMID 41850056 ↗Journal Poult SciYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41850056/
-
Observational / other LOW evidence YELLOWPretreatment of soybean hulls hemicellulose in ionic liquid facilitates anti-inflammatory oligosaccharides preparation. ↗Liu F et al.. Pretreatment of soybean hulls hemicellulose in ionic liquid facilitates anti-inflammatory oligosaccharides preparation.. Food Chem. 2026. PMID:41844105.PMID 41844105 ↗Journal Food ChemYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41844105/
Score Transparency
0 of 10 approved references (score saturates at 10). More peer-reviewed studies = stronger evidence base.
Method: Q = number of approved references ÷ 10 (capped at 1.0)
Limited — mostly case reports or animal studies
Method: L = mean study-level weight across approved references. Level 1 (meta-analysis / systematic review) = 1.0; Level 2 (RCT) = 0.8; Level 3 (cohort/case-control) = 0.6; Level 4 (case report) = 0.4; Level 5 (animal / in-vitro) = 0.2.
Mixed or neutral — roughly equal benefit and risk signals
Method: D = (sum of risk-scored references − sum of benefit-scored references) ÷ total evidence score, then scaled from [−1, 1] to [0, 1]. 0.0 = pure benefit; 0.5 = neutral; 1.0 = pure risk.
One or more monitoring-level safety signals active
Method: S = 0.5 (neutral baseline) + sum of active signal severity deltas ÷ 10. Severity deltas: Critical = +2.0, High = +1.5, Moderate = +1.0, Low = +0.5. Capped at 1.0.
Final GIRI Score for Xylanase. Risk level thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.
Full methodology & data sources
The GIRI Score is computed entirely from structured data — no editorial scoring or subjective weighting is applied at any step.
- References: Only approved references are counted. Each reference is assigned an evidence level (L1–L5) and a direction (risk / neutral / benefit) by the reference manager or AI classifier.
- Safety Signals: Sourced from regulatory agencies (FDA, EMA, Health Canada, TGA, and others) and pharmacovigilance databases. Only active signals count toward the score.
- Formula version: GIRI Score v3.7.0 — Q × L × D × S × 10.
- Limitations: The score reflects published evidence and recorded signals as of the last update date. It is not a clinical risk assessment and should not replace advice from a qualified healthcare professional.
Risk Level Classification
Based on available regulatory signals and scientific evidence, this ingredient presents a low safety concern under normal conditions of use.
0–3.0
3.0–5.5
5.5–7.5
7.5–10
The score pin shows exactly where this ingredient falls on the fixed risk scale.
What drove the Low classification for Xylanase
A score of 1.0 places this ingredient in the Low band. Thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.
0 approved references.
Limited — mostly case reports or animal studies (Level 4–5).
Neutral or mixed — benefit and risk signals roughly balanced.
No active signals — S component is at neutral baseline (0.5), contributing no extra risk weight.
No major regulatory restrictions or advisories recorded across monitored jurisdictions (FDA, EMA, Health Canada, TGA, and others).
How are the Low / Moderate / High / Critical thresholds defined?
The four risk levels are fixed score bands. A score is assigned to exactly one level based on where it falls:
| Level | Score | Meaning |
|---|---|---|
| LOW | 0.0 – 2.9 | Sparse or predominantly beneficial evidence. No active safety alerts. |
| MODERATE | 3.0 – 5.4 | Mixed signals — some risk alongside benefit. Caution at high doses or in sensitive groups. |
| HIGH | 5.5 – 7.4 | Multiple studies or regulatory alerts documenting adverse effects. Professional oversight recommended. |
| CRITICAL | 7.5 – 10 | Regulatory restrictions in one or more major jurisdictions. Serious documented harm. Avoid without specialist supervision. |
Thresholds are fixed constants (GIRI_Score_Utils::LEVEL_THRESHOLDS). They do not change per ingredient and are never subject to editorial adjustment.